Nuvalent Submits Neladalkib NDA, Reaffirms Zidesamtinib PDUFA Date

What happened

Nuvalent announced the submission of its NDA for neladalkib in TKI-pretreated ALK-positive NSCLC, a key milestone guided for the first half of 2026. The company also noted the FDA is reviewing its zidesamtinib NDA for ROS1-positive NSCLC with a September 18, 2026 PDUFA date, and plans a label expansion submission for zidesamtinib in the second half of 2026. Management reiterated pipeline progress and reported first-quarter financial results, emphasizing an improved leadership team. While the neladalkib NDA submission removes a major near-term uncertainty, it does not guarantee FDA acceptance or a smooth review; investors should watch for acceptance within 60 days. Nuvalent still faces significant commercial execution risks, including revenue-sharing obligations that will dilute per-share value even if approvals are granted.

Implication

Nuvalent's thesis now hinges on zidesamtinib's PDUFA decision on September 18, 2026, and eventual commercial execution. The neladalkib NDA submission de-risks the second catalyst but does not assure approval. Competitive dynamics in ALK/ROS1 NSCLC and revenue-sharing obligations (low-single-digit plus 1.5% net sales) limit upside. Investors should monitor for FDA review issues and commercialization progress. The stock likely trades range-bound until the zidesamtinib decision, with potential for a sell-the-news reaction on any positive milestone.

Thesis delta

The key near-term catalyst—neladalkib NDA submission—has been confirmed, shifting risk from whether the filing would occur on time to whether the FDA will accept it. This supports the bull case (target $135) if acceptance is clean, but does not yet validate the full thesis. The re-assessment window now moves to FDA acceptance (within 60 days) and the zidesamtinib PDUFA date. The thesis remains a 'wait' until acceptance is confirmed or the stock pulls back to a margin-of-safety entry near $85.